Results 281 to 290 of about 60,513 (321)

Prognostic Implications of Red Blood Cell Distribution Width to Albumin Ratio in Myelofibrosis: A 10-Year Multicenter and Retrospective Study. [PDF]

J Inflamm Res
Zeng T, Zheng Z, Qian H, Liu L, Shi X, Shao Y, Huang Z, Li R, Wen B, Han Q, Feng Q, Tu L, Bao X, Tong H, Jin J, Huang J.   +15 more
europepmc   +1 more source

Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis. [PDF]

Future Oncol
Masarova L, Verstovsek S, Palandri F, Mesa R, Harrison C, Dobi B, Gorsh B, Wang Z, Ellis C, Patnaik D, Liu T, Kapetanakis V.   +11 more
europepmc   +1 more source

European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.

MARCHETTI M, Vannucchi A, Mascarenhas J, Alvarez-Larran A, Bose P, Gale R, Harrison C, Hehlmann R, Kiladjian J, Koschmieder S, Mesa R, Passamonti F, Rambaldi A, Tefferi A, Barbui T.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia

Expert Review of Hematology, 2022
Introduction Myelofibrosis (MF) is a rare myeloproliferative neoplasm characterized by a complex symptom profile, cytopenias, splenomegaly, and potential for leukemic progression.
J. Mascarenhas
semanticscholar   +1 more source

Pharmacotherapy of Myelofibrosis

Drugs, 2017
Myelofibrosis (MF) is a myeloproliferative neoplasm that is pathologically characterized by bone marrow myeloproliferation, reticulin and collagen fibrosis, and extramedullary hematopoiesis. Constitutive activation of the Janus associated kinase (JAK)-signal transducers and activators of transcription signaling pathway with resultant elevation in pro ...
Douglas Tremblay, Bridget K. Marcellino, John Mascarenhas   +2 more
openaire   +2 more sources